Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, August 5 at 2:00 PM EDT

Register Free →

Get CLEATUSFree Trial

Get CLEATUSFree Trial

Search

Top

1575 EYE STREET ASSOCIATES

UEI: RMYCEA9KRF35

1575 EYE STREET ASSOCIATES is a federal contractor, registered under UEI RMYCEA9KRF35. It has been awarded $118,795 across 2 federal contracts. Primary work spans Unknown NAICS and Unknown NAICS. Top awarding agencies include General Services Administration and Department Of Veterans Affairs.

Contact Information

Registration and classification details

Registration

UEI Code

RMYCEA9KRF35

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

Key Performance Metrics

Awards Count

0

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency

General Services Administration$84.0K70.7%

Department Of Veterans Affairs$34.8K29.3%

Awards by NAICS

- Unknown NAICS$84.0K70.7%

233320 - Unknown NAICS$34.8K29.3%

Awards by Agency Over Time

Awards by Place of Performance

Open opportunities in 1575 EYE STREET ASSOCIATES's top NAICS codes and agencies

Intent to Sole Source: Upgrade services for Iraimed MR400 System

Department Of Veterans Affairs

POSTED

DEADLINE

in about 15 hours

Revlimid_BPAThe Department of Veterans Affairs (VA), through Network Contracting Office 15, awarded a 12-month Blanket Purchase Agreement (BPA) to Bristol-Myers Squibb for the brand-name pharmaceutical REVLIMID® (lenalidomide) capsules, commencing February 2, 2026, and ending February 1, 2027. This BPA was established as a sole-source 8(a) set-aside under GSAM/R 538.7104-3 due to the unique and highly specialized nature of REVLIMID®, which is subject to the FDA-mandated Lenalidomide Risk Evaluation and Mitigation Strategy (REMS) program. The sole source award reflects the clinical necessity of using the brand-name product for certain patients intolerant to generic alternatives and the restrictive distribution requirements that limit supply to REMS-certified pharmacies. The program ensures uninterrupted access to the medication across the VA’s Veterans Integrated Service Networks (VISNs), replacing an expiring McKesson contract. This BPA is situated under Bristol-Myers Squibb's Federal Supply Schedule (FSS) contract and does not include option periods, indicating an interim emergency acquisition to avoid treatment disruptions. The procurement is governed by compliance with REMS-certified dispensing, strict brand-name exclusivity, and FDA requirements, with a focus on patient safety and supply chain reliability. Key administrative contacts include contracting officers and specialists located at the VA contracting office in Leavenworth, KS, while delivery and acceptance occur at VA medical centers and REMS-certified pharmacies nationwide. Pricing details and specific contract values were not disclosed, but the award is based on a best-value trade-off emphasizing regulatory compliance, product uniqueness, and clinical imperatives rather than low cost. Inspection and acceptance rely primarily on adherence to REMS protocols and FDA specifications rather than physical inspection standards. Overall, the contract underscores a specialized federal procurement tailored to the unique pharmaceutical and clinical needs of the Veterans Health Administration.

Department Of Veterans Affairs

POSTED

DEADLINE

Invoice Processing and Payment CoordinationThis contract involves managing the invoicing and payment coordination process for Revlimid® prescriptions following the discontinuation of the McKesson-based invoicing system previously in use. It requires integration with existing Department of Veterans Affairs (VA) systems to ensure a seamless transition and continued efficient handling of prescription billing and payments. The work is classified under NAICS code 541512, which pertains to computer systems design services, indicating a technology-driven solution to support invoicing operations. The contract is a subcontract awarded under the 8(a) Sole Source program, reflecting its status as a specialized arrangement aimed at supporting a veteran-focused federal agency. Specific location details are not provided, suggesting the possibility of a remote or multi-site engagement. This effort is critical to maintaining uninterrupted service delivery for revlimid prescription invoicing within the VA’s healthcare system, emphasizing the importance of technical integration and payment processing accuracy.

Department Of Veterans Affairs

POSTED

DEADLINE

Brand-Name Pharmaceutical Supply (No Substitution)The contract involves the supply of original manufacturer Revlimid® capsules in multiple strengths, ensuring that only brand-name products are provided with no substitutions allowed. This requirement is driven by patient intolerance to generic versions of the medication. The arrangement is designated as a sole-source, brand-only subcontract under the 8(a) set-aside category, reflecting a preference or requirement for a specific supplier due to unique product specifications or circumstances. The Department of Veterans Affairs is the contracting agency, highlighting the focus on providing medications tailored to the needs of veterans who require this specific brand medication. Although specific location details for performance and points of contact are not provided, the contract falls under the NAICS code 325412, which relates to pharmaceutical manufacturing, indicating the nature of the product and supplier. The solicitation was posted on February 6, 2026, emphasizing the urgency and particular nature of the procurement.

Department Of Veterans Affairs

POSTED

DEADLINE

REMS-Certified Specialty Pharmacy DistributionThis contract involves the distribution of the brand-name drug Revlimid® exclusively to Department of Veterans Affairs (VA) patients across the nation. The distribution must be conducted through a specialty pharmacy network that complies with the Risk Evaluation and Mitigation Strategy (REMS) requirements, ensuring strict adherence to safety protocols and oversight. No substitutions with generic or alternative medications are permitted, emphasizing the necessity of dispensing the specified brand-name product. The contract is designated as a subcontract under the NAICS code 424210, which pertains to pharmaceutical preparation and distribution. It is set aside as an 8(a) Sole Source contract, indicating it is awarded without a competitive bidding process under a specific small business development program. The Department of Veterans Affairs is the contracting agency, underscoring its commitment to providing specialized pharmaceutical care to veterans in a highly controlled and compliant manner.

Department Of Veterans Affairs

POSTED

DEADLINE

Department of Veterans Affairs, VA Innovation Ecosystem (VHAIE); Broad Agency Announcement (BAA); Suicide PreventionThe Department of Veterans Affairs, through its VA Innovation Ecosystem (VHAIE), is issuing a Broad Agency Announcement (BAA) to solicit concept papers from a wide range of organizations—including private companies, non-profits, and academic institutions—for innovative solutions in suicide prevention, care coordination, and treatment for Veterans. Submissions will be accepted from July 15, 2024, through September 30, 2026, and must be sent to VHASuicidePreventionBAA@va.gov. The initiative is designed to support early-stage research, development, prototyping, and piloting, with an emphasis on advancing the state of the art in service delivery and operational effectiveness. The primary objectives of this opportunity are to increase Veterans’ access to suicide prevention services, control or reduce associated costs, enhance the performance of VA operations, and improve the quality of care provided to Veterans and their families. VHAIE aims to foster both incremental and transformational innovation through agile and flexible mechanisms that empower employees and drive organizational capability. The solicitation is open to various entities and is focused on sourcing cutting-edge research and practical solutions that align with the VA’s mission to best serve the Veteran community. The official posting resides in Washington, District of Columbia, under solicitation number 36C10X24R0053, and further details are accessible via the provided government contract link.

Department Of Veterans Affairs

POSTED

DEADLINE